Introduction
The field of cell-death research has matured since pioneering discoveries showed that apoptosis is regulated genetically. Although many of the core caspase-signalling pathways are known, some of the most basic aspects of the biochemistry of mitochondrial apoptosis induction have remained elusive and are, in certain cases, controversial. Research on the metabolic dysfunction that occurs in cancer cells has led to the emergence of new drug targets, and recent studies have identified novel cell-death pathways. These exciting developments were discussed at the recent Keystone Symposium on Cell Death Pathways in Whistler, Canada. Many elegant studies were presented at the meeting; unfortunately, we cover only a few key topics here owing to space limitations. This report highlights presentations on the connections between cell death and mitochondrial dynamics, metabolism and cancer, and non-apoptotic cell death.
Fission, fusion and the MOMP confusion
Mitochondrial outer membrane permeabilization (MOMP) is an important regulator of apoptosis that results in cyt c and Smac release, and in caspase activation. Many models for MOMP have been put forward, often involving pro-apoptotic Bcl-2 family members such as Bax and Bak. Recent findings show that Bcl-2 family members also influence mitochondrial fission and fusion (reviewed in Suen et al, 2008) . Fission and fusion occur during normal cellular homeostasis; however, evidence suggests that these organelle interactions could also affect apoptosis signalling.
Several models of the interplay between MOMP and fission/ fusion were discussed at the meeting. R. Youle (Bethesda, MD, USA) suggested that the mitochondrial fission/fusion machinery is important for cyt c release (Suen et al, 2008) . Bax and the profission GTPase Drp1 co-localize at foci on the mitochondrial membrane, and these foci subsequently turn into fission sites. His group detected Bax translocation, mitochondrial fragmentation and cyt c release almost concomitantly. Interestingly, Bax/Bak-knockout cells contain short mitochondria and have lower rates of mitochondrial fusion (Karbowski et al, 2006) . J.C. Martinou (Geneva, Switzerland) hypothesized that Drp1 facilitates Bax aggregation and oligo merization at mitochondrial constriction sites, thereby facilitating pore formation. The overexpression of a mutant Drp1 that fails to stimulate Bax oligo merization delays cyt c release and apoptosis induction (Parone et al, 2006) . Martinou further suggested that MOMP is the outcome of dysfunctional membrane fission. By contrast, S. Martin (Dublin, Ireland) showed that although Bax and Bak can modulate fission and fusion, these events are not required for cyt c release and apoptosis (Sheridan et al, 2008) , as reviews meeting repor t the expression of a dominant-negative Drp1 does not inhibit either event. Furthermore, although various anti-apoptotic Bcl-2 family members inhibit cell death, they do not block mitochondrial fission or cristae rearrangements.
Although many groups are investigating the mechanism of MOMP, and the relationship between Bax and Bak and mitochondrial fission/fusion, the precise mechanisms are still unclear and there are many conflicting results. However, the idea that Bcl-2 family proteins can have dual effects in cell death and mitochondrial fission/fusion is convincing. Martin suggested that the switch for these different roles is determined by BH3-only proteins. Some BH3 domains show signi ficant structural plasticity upon protein binding (Smits et al, 2008) , which might result in a change of protein function. For example, Bcl-2 switches from protector to killer upon binding a short peptide (Kolluri et al, 2008) .
It is not surprising that the specific mechanisms of MOMP remain a mystery; mitochondria are heterogeneous and subcompartmentalized, and interact with each other and with other organelles. A 'dirty little secret' is that cell-death researchers often use crude heavy-membrane fractions as 'mitochondria'. This fraction contains other structures that might influence apoptosis signalling. D. Green (Memphis, TN, USA) showed that using crude mitochondria can lead to new insights into an old apoptosissignalling concept: the induction of apoptosis by the sphingo myelin pathway. The involvement of sphingomyelin-derived metabolites in pro-apoptotic mitochondrial alterations identified by the Green laboratory is different from what has been proposed in previous studies on the putative involvement of ceramide or sphingo myelin receptor-mediated apoptosis. Green showed that sphingolipids could regulate the Bcl-2 family effector proteins Bak and Bax, in order to promote their activation, oligomerization and MOMP. This was also demonstrated in protein-free liposomes, in which sphingolipid meta bolites markedly increased permeabilization by Bax and cleaved Bid. Interestingly, the removal of endoplasmic reticulum desensitized mitochondria to BH3-only proteins owing to a lack of sphingo myelinase activity. Green speculated that the endoplasmic reticulum might affect apoptosis signalling by providing a lipid milieu for mitochondria that assists the activation of Bax/ Bak. As the most commonly used mitochondrial isolation protocols result in a heavy-membrane fraction containing both mitochondria and the endoplasmic reticulum-not to mention lysosomes-this is something to keep in mind in further studies.
Metabolism, cell death and glutamine addiction
Although mitochondria are a keystone of apoptotic events, they are also essential for cell survival because they provide energy to cells through respiration. Crosstalk occurs between the metabolism and apoptosis pathways in response to changes in nutrient availability. For example, T cells require growth factors to stimulate glucose uptake, and undergo p53-dependent apoptosis after growth-factor withdrawal. As discussed by J. Rathmell (Durham, NC, USA), the expression of the glucose transporter Glut1 induces glucose uptake and inhibits Bax activation in activated T cells (Zhao et al, 2008) . This is regulated by the anti-apoptotic Bcl-2 protein Mcl-1, which is stabilized in response to glucose uptake. After growth-factor withdrawal, glycogen synthase kinase 3 targets Mcl-1 for degradation, p53 signalling induces the expression of Bim and Puma, and apoptosis is initiated. Glut1 expression is sufficient to suppress p53 activity after growth-factor withdrawal, and cell death can be inhibited by knocking out both Bim and Puma. Rathmell suggested that Bim, which is downstream of the endoplasmic reticulum-stress pathway, and Puma, which is downstream of the metabolic-stress pathway, work in parallel to initiate apoptosis in response to glucose deprivation.
Apoptosis induction can also be triggered by metabolic changes downstream of glucose uptake. S. Kornbluth's (Durham, NC, USA) work in oocytes provided insight into how cells sense metabolic changes and initiate apoptosis during development. NADPH produced by the pentose phosphate pathway inhibits apoptosis in Xenopus oocytes (Nutt et al, 2005) . This is mediated by the phosphorylation of caspase 2. Kornbluth proposed that a similar mechanism occurs in Drosophila S2 cells. She showed that a cell-permeable malate analogue-predicted to increase NADPH productionrescued DHEA-induced cell death, which is caused by reduced NADPH levels and increased caspase activity. Kornbluth suggested that malate inhibits apoptosis by preventing DHEA-mediated dephosphorylation of the Dronc prodomain. Although it is usually considered to be a caspase 9 homologue, Kornbluth proposed that Dronc is more similar to caspase 2 and-like Xenopus caspase 2-might act as a metabolic sensor of apoptosis.
Tumours have high metabolic rates in order to sustain rapid cell growth and division, and there is a renewed focus on determining how tumour cells can continue to proliferate as they deplete essential macro molecules. In addition to glucose, many cells also require glutamine for survival. Glutamine is metabolized at a tenfold higher rate by cancer cells than by normal cells, although only 10% is used for showed that glutamine is required for the activity of the Krebs cycle, and that the inhibition of glutamine metabolism through the Krebs cycle induces Myc-dependent apoptosis (Yuneva et al, 2007) . Furthermore, the Krebs cycle substrates pyruvate and oxaloacetate can protect Myc-transformed fibroblasts from apoptosis induced by glutamine deprivation. Similarly, Thompson showed that the replacement of glutamine with α-ketoglutarate allows cells to survive in the absence of serum. Future studies will elucidate the complex relationship between metabolism and cell death in more detail. It is hoped that an increased understanding of metabolic regulation will lead to in vitro models that better mimic the in vivo tumour microenvironment.
On the horizon: cancer treatment and prevention
Understanding metabolic-pathway function during tumour development is leading directly to new ideas for therapeutic intervention. J. Brugge (Boston, MA, USA) uses three-dimensional mammary cellculture models to investigate mammary morpho genesis. Mammarylumen formation requires Bim-mediated apoptosis; however, in the absence of Bim, inner cells undergo rampant autophagy and eventually die through non-apoptotic cell death (Mailleux et al, 2007) . Cells that are deprived of extra cellular matrix in vitro have reduced ATP levels and high levels of ROS owing to defects in glucose uptake. However, oncogenes such as ErbB2 can elevate ATP levels by rescuing glucose metabolism. Interestingly, antioxidants can also elevate ATP levels by rescuing the ROS inhibition of fatty-acid oxidation. Therefore, Brugge suggests that the survival of tumour cells outside their natural matrix niches requires alterations that prevent apoptosis and rescue metabolic defects caused by a loss of glucose uptake. Furthermore, the elevation of tumour-cell antioxidant activity could suppress the natural mechanisms that eliminate aberrantly proliferating cells and promote tumour-cell survival.
Research into cancer-cell metabolism is also leading to new ideas for cancer prevention. The monoallelic loss of the autophagy gene beclin1 is prevalent in human cancers, suggesting that autophagy is tumour suppressive even though it also occurs in tumour cells as a survival mechanism. E. White (New Brunswick, NJ, USA) showed that autophagy-defective cells accumulate p62-protein aggregates in response to metabolic stress (Mathew et al, 2009) , which is accompanied by elevated ROS production, accumulation of damaged mitochondria and activation of the DNA-damage response. The suppression of p62 accumulation in autophagy-defective tumour cells rescues oxidative stress and prevents the activation of the DNA-damage response. Importantly, this aberrant and persistent p62 accumulation in autophagy-defective cells promotes altered gene expression and tumorigenesis. Therefore, the autophagic degradation of p62 protects cells from damage that can lead to tumour formation; this led White to propose that autophagy promoters could be used to prevent cancer in some circumstances.
Several candidate anticancer therapeutics have recently emerged from cell-death research. J.P. Medema (Amsterdam, the Netherlands) showed that BetA induces autophagy and cell death, in addition to a mitochondrial morphology similar to that of patients with Barth syndrome. BetA-mediated cell death is dependent on mitochondrial permeability transition, and specifically induces death in tumour cells while untransformed cells remain healthy (Mullauer et al, 2009) . BetA variants with a higher cell permeability could be interesting therapeutics.
New drug strategies that target Bcl-2 family proteins have also emerged. A. Strasser (Parkville, Australia) found that Bcl-xL-but not Bcl-2-is required for lymphoma development in Eμ-Myc transgenic mice (Kelly et al, 2007) . A loss of Bcl-xL reduced the abnormal accumulation of pre-B cells caused by the over expression of Myc, and accelerated the apoptosis of pre-leukaemic cells. The mono allelic loss of Bim restored the ability of Myc to induce pre-B/ B-cell lymphoma development in the absence of Bcl-xL. Treatment with the BH3-targeting drug ABT-737 notably blocked the development of Eμ-Myc lymphoma, and reduced the number and accelerated the apoptosis of pre-leukaemic Eμ-Myc B cells. Therefore, BH3-targeting drugs have the potential to be effective in the treatment of lymphoma. Furthermore, BH3-targeting drugs can be made more effective through combinatorial treatment. HDAC inhibitors-such as vorinostat-selectively kill tumour cells through the mitochondrial pathway (Ellis et al, 2009) , although the over expression of pro-survival Bcl-2 proteins, which are common in cancers, prevents the effect of HDAC inhibitors. By using an Eμ-Myc mouse model, R. Johnstone (Melbourne, Australia) demonstrated that the efficacy of HDAC inhibitors in cancer therapeutics could be increased by the combinatorial treatment of ABT-737 with vorinostat. Bmf is a transcriptional target of vorinostat, which induces histone hyperacetylation within the Bmf promoter region. The vorinostat/ABT-737 synergistic effect is lost if Bmf is knocked down, indicating that Bmf is functionally important in this drug combination.
Genetic heterogeneity affects tumour progression and response to chemotherapy, thereby creating serious obstacles to cancer treatment. By using mouse models for AML, S. Lowe (Cold Spring Harbor, NY, USA) recapitulated the differences in response to chemotherapy that are associated with various genotypes. A retroviral approach that conditionally suppresses gene function in vivo led to the discovery of genes that are required for leukaemic maintenance (Zuber et al, 2009 ). Mouse models of AML with common human AML mutations were used to correlate different mutations with disease prognosis. Poorly responding leukaemias showed a marked attenuation of the p53 response, which might explain their drug resistance. Therefore, Lowe suggests that genetic information and assessment of p53 activation should be used to guide human AML treatment.
Although surprisingly few cancer drugs have resulted from celldeath research so far, recent advances are promising. Furthermore, new developments from the field of death receptor-mediated pathways, although not the focus of this meeting, are also promising and might lead to additional drug candidates. It will be exciting to follow the development of combinatorial treatments, as well as those that take advantage of genetic information.
New frontiers in the world of cell death
We have long known about multiple forms of cell death; however, relatively little is known about non-apoptotic death mechanisms. The depletion of Hsp70-a survival protein that is highly expressed in many cancers-induces a caspase-independent cell death reviews meeting repor t that requires the release of lysosomal cathepsin into the cytosol (Nylandsted et al, 2004) . M. Jäättelä (Copenhagen, Denmark) described changes in lysosomal composition, trafficking and function that occur during cancer transformation and progression (Fig 1; supplementary Movie S1 online). Jäättelä found that Hsp70 binds to lysosomal lipids, thereby stabilizing lysosomes in cancer cells and suggesting that Hsp70-expressing cancer cells might be resistant to lysosome-targeting drugs. Non-apoptotic cell death might also occur during development. K. McCall (Boston, MA, USA) reported that the lysosomal proteins Spinster and Deep Orange are required for nursecell death in the developing Drosophila egg chamber (Peterson et al, 2007) , which is caspase independent and requires cell-autonomous DNase-II activity. Her results suggest that lysosomes surround nursecell nuclei and rupture during the late stages of nurse-cell death. S. Shaham (New York, NY, USA) described a new form of cell death in Caenorhabditis elegans development-the cell-autonomous death of linker cells-that is also observed during mammalian development. Interestingly, a genetic screen identified a requirement for several developmental-timing genes in this pathway, whereas apoptosis and autophagy genes did not seem to be involved (Abraham et al, 2007) . Finally, F. Chan (Worcester, MA, USA) described a type of caspase-independent cell death known as programmed necrosis. This process requires RIP1, which also mediates NF-κB activation. Chan showed that RIP3 is required for the phosphorylation and stable binding of RIP1 to FADD, allowing the formation of a RIP1-FADD-RIP3 complex. The RIP3-mediated activation of RIP1 results in a transient induction of necrosis-associated kinase activity. Vaccinia virus-infected RIP3 -/-mice do not have necrotic tissue injury or virus-induced inflammation. These mice fail to control viral infection, suggesting that programmed necrosis could be a potential antiviral-defence mechanism.
Although we have long known about alternative forms of cell death, the mechanisms of these types of cell suicide are still elusive. In addition, little is known about how alternative death mechanisms are regulated. Undiscovered cell-death reg ulators might exist and/or known death regulators could function in a manner that is cell context-specific. Ultimately, we cannot exclude the possibility that the regulation of apoptotic and non-apoptotic mechanisms might be similar. Further research will be necessary to resolve these questions.
Summary
The 2009 Keystone Symposium on Cell Death Pathways showcased exciting research on many aspects of cell death. Here we have highlighted a few of these discoveries. Although much is known about mitochondrial dynamics, metabolism and cell death, we are just beginning to understand the relationships among these processes. These discoveries, together with new findings about non-apoptotic cell death, have the potential to influence cancer treatment. We can therefore proclaim that cell-death research is not dead-fundamental discoveries will be made about how cells die as new models and methods emerge. 
